Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients
| dc.authorid | 0000-0003-0230-6575 | |
| dc.authorid | 0000-0003-2714-4584 | |
| dc.authorid | 0000-0002-4281-0867 | |
| dc.authorid | 0000-0003-2995-8792 | |
| dc.authorid | 0000-0003-1919-3183 | |
| dc.authorid | 0000-0001-5825-8627 | |
| dc.authorid | 0000-0003-1516-1811 | |
| dc.authorid | 0000-0002-4951-6716 | |
| dc.contributor.author | Çakal, Beytullah | |
| dc.contributor.author | Çakal, Sinem Deniz | |
| dc.contributor.author | Karaca, O?uz | |
| dc.contributor.author | Omaygenç, Mehmet Onur | |
| dc.contributor.author | Kızılırmak Yılmaz, Filiz | |
| dc.contributor.author | Güneş, Hacı Murat | |
| dc.contributor.author | Özcan, Özgür Ulaş | |
| dc.contributor.author | Yıldırım, Arzu | |
| dc.contributor.author | Boztosun, Bilal | |
| dc.date.accessioned | 2021-02-12T06:44:09Z | |
| dc.date.available | 2021-02-12T06:44:09Z | |
| dc.date.issued | 2020 | |
| dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalı | |
| dc.description.abstract | Introduction: Elevated risk of adverse events in comparison to metallic stents resulted in withdrawal of everolimus-eluting bioresorbable scaffolds (eBVS), known as the most intensively studied BVS. There is a paucity of data comparing the two different BVS. Aim: To evaluate the long-term clinical outcomes of the novolimus-eluting bioresorbable vascular scaffold (nBVS) compared with eBVS. Material and methods: Consecutive patients treated with nBVS or eBVS in our center were screened. The primary outcome was the 3-year rate of major adverse cardiovascular events (MACE), defined as the composite of cardiac death, target vessel myocardial infarction (TV-MI), and target-lesion revascularization (TLR). Results: After matching, 98 patients treated with 135 eBVS were compared with 98 patients treated with 136 nBVS. Baseline characteristics, clinical presentation, and lesion characteristics were comparable in both groups. The 3-year MACE rate was higher in the eBVS group (17.3% vs. 6.1%; p log-rank = 0.02). The occurrence of TLR (16.3% vs. 5.1%; p log-rank = 0.02) and TV-MI (8.2% vs. 0 %; p log-rank = 0.004) was also higher in the eBVS group except for cardiac deaths (1% vs. 2%; p log-rank = 0.98, eBVS vs. nBVS, respectively). Of note, definite device thrombosis rate was markedly increased in the eBVS group (5.1% vs. 0%; p log-rank = 0.03). Conclusions: The present study revealed that the 3-year event risk was lower for nBVS compared to eBVS. More evidence is needed to evaluate long-term performance of novolimus-eluting biovascular platforms. | |
| dc.identifier.citation | Çakal, B., Çakal, S. D., Karaca, O., Omaygenç, M. O., Kızılırmak Yılmaz, F., Güneş, H. M. ... Boztosun, B. (2020). Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients. Postepy w Kardiologii Interwencyjnej, 16(4), 391-398. https://dx.doi.org/10.5114/aic.2020.101763 | |
| dc.identifier.doi | 10.5114/aic.2020.101763 | |
| dc.identifier.endpage | 398 | |
| dc.identifier.issn | 1734-9338 | |
| dc.identifier.issue | 4 | |
| dc.identifier.scopusquality | Q3 | |
| dc.identifier.startpage | 391 | |
| dc.identifier.uri | https://dx.doi.org/10.5114/aic.2020.101763 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12511/6554 | |
| dc.identifier.volume | 16 | |
| dc.identifier.wosquality | Q4 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Termedia Publishing House Ltd. | |
| dc.relation.ispartof | Postepy w Kardiologii Interwencyjnej | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | Attribution-NonCommercial-ShareAlike 4.0 International | * |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
| dc.subject | Coronary Artery Disease | |
| dc.subject | Percutaneous Coronary Intervention | |
| dc.subject | Bioresorbable Scaffolds | |
| dc.title | Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients | |
| dc.type | Article |
